Alembic Pharmaceuticals Q4 FY26: Steady growth, higher R and D, and a new US branded bet

Alembic Pharmaceuticals closed Q4 FY26 with a mixed but directionally important update. Revenue from operations rose to INR 1,848 crore, up 4 percent year-on-year. EBITDA before R and D came in at INR 455 crore, translating into a 25 percent margin versus 24 percent a year ago. Reported profit after tax was INR 203 crore, aided by one-time tax adjustments of INR 101 crore, alongside an exceptional item of INR 24 crore.

The operating context, as management framed it on the call, remains demanding. Pricing pressure, competitive intensity, regulatory expectations, and supply chain volatility are still shaping outcomes. Against that backdrop, Alembic is leaning on execution levers: protecting gross margins, improving operating leverage, and investing selectively in future growth platforms.

Business performance: four engines, different speeds

The company continues to run a diversified model across India branded formulations, US generics, ex-US formulations, and APIs. FY26 revenue from operations was INR 7,345 crore, up 10 percent year-on-year, with a fairly balanced mix across the four pillars.

India branded business delivered Q4 revenue of INR 568 crore, up 4 percent, and FY26 revenue of INR 2,458 crore, up 5 percent. Management said the quarter was supported by price-led growth and new launches, with specialty therapies and animal healthcare performing relatively better within the portfolio. The company also highlighted that the Indore facility is fully operational, with improving utilisation, which should support supply reliability and operating efficiency.

Animal health, disclosed as a focused area within the India portfolio, posted a stronger quarter. Q4 revenue rose 27 percent year-on-year to INR 124.1 crore, while FY26 reached INR 519.1 crore. The presentation cited leadership in haematinics and antibiotics, and called out brands such as Sharkoferrol, Moxel, Xcseft and McEft.

The US generics business remained the key growth driver in Q4. Revenue rose 11 percent year-on-year to INR 564 crore and grew 13 percent for FY26 to INR 2,206 crore. The company reported a cumulative 274 ANDA filings and 235 approvals (including 19 tentative approvals), with 178 products launched so far. In FY26 alone, 15 products were launched. Management indicated that launches and market share gains supported the quarter.

Ex-US formulations had a softer quarter but a strong year. Q4 revenue declined 2 percent year-on-year to INR 369 crore, which management attributed to a higher base and one-off variances. FY26 revenue rose 20 percent to INR 1,494 crore, supported by launches and expansion. The company highlighted partnerships across Europe, Canada, Australia, Brazil, Chile and South Africa, and noted that subsidiaries have been set up in Thailand, the Philippines and Germany to support geographic diversification.

API revenue increased 2 percent year-on-year in Q4 to INR 347 crore. For FY26, API revenue grew 5 percent to INR 1,187 crore. Management reiterated that volumes were supportive but pricing remains a headwind, and the response is centred on cost efficiency and portfolio choices. The company filed 6 US DMFs in Q4 and reported 149 cumulative US DMF filings.

Note: EBITDA before R and D is explicitly disclosed for Q4 FY26 in the presentation; FY-level pre R and D EBITDA is referenced in the concall but the presentation P and L table provides EBITDA margins, not absolute EBITDA.

R and D and the pipeline: higher spend, higher ambition

R and D spend rose sharply in Q4, reaching INR 209 crore, or 11 percent of revenue, versus INR 151 crore and 9 percent in Q4 FY25. Management attributed this to peptide-related development activities and higher filings across the US and ex-US markets.

For the year, the presentation disclosed R and D spend of INR 710 crore in FY26, equivalent to 9.6 percent of sales. In the concall, management said the Q4 intensity was an outlier and that they expect it to trend back closer to about 9 percent.

The pipeline continues to expand, but management’s emphasis is shifting. They stated that portfolio choices are being calibrated towards higher value opportunities, including NCE-1, first-to-file and day 1 molecules. They also noted that complex and peptide developments can be more expensive, which partly explains periodic spikes.

The strategic pivot: US branded business begins

The most meaningful strategic development in the quarter was the start of a US branded business. The company launched its first branded product, Pivya, in Q4 FY26. Management described the initiative as a calibrated entry intended to build a sustainable specialty platform over time rather than pursuing rapid scale.

The near-term trade-off is profitability. Management acknowledged a margin drag from the launch phase. The CFO suggested that, for modelling purposes, the branded effort had around a 100 to 150 basis points impact on margins, and management expects another quarter or two of drag. The stated plan is to offset this through improved operating leverage in the core generics and API business.

FY27 directional view: growth with discipline

For FY27, management provided directional guidance rather than a strict forecast. At a consolidated level, Alembic is targeting low double-digit top line growth. International generics are expected to grow in the low to mid-teen range, while API is expected to grow in the high single to low double-digit range. The company also expects the India business to improve and move closer to market growth.

On investments, R and D spend is expected to be around INR 750 to 800 crore. Capex is guided at INR 300 to 350 crore, largely towards capacity, debottlenecking and replacement, indicating a relatively moderate capital intensity versus past build-outs.

The key execution variables for the year include the pace and quality of launches, utilisation improvement across facilities, and whether the US branded franchise can scale without creating a prolonged margin overhang.

Takeaways for investors

Alembic’s Q4 FY26 update reinforces a familiar pattern in Indian pharma: steady base business execution, punctuated by strategic bets that can temporarily blur reported profitability. The quarter’s headline PAT also carried one-time tax adjustments, so the underlying story is better read through the operating narrative.

FY26 showed broad-based growth across businesses, with ex-US delivering strong full-year momentum and the US generics engine continuing to expand its portfolio. FY27, as management laid out, is about translating this platform into higher quality growth, while absorbing the launch-phase costs of a new US branded initiative and maintaining margin protection in a still-competitive global environment.